<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">antibiotics-273</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Профилактика и терапия экспериментальной формы лихорадки Западного Нила рибавирином</article-title><trans-title-group xml:lang="en"><trans-title>Ribavirin Prophylaxis and Therapy of Experimental West Nile Fever</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Логинова</surname><given-names>С. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Loginova</surname><given-names>S. YA.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Борисевич</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Borisevich</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пащенко</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Pashchenko</surname><given-names>YU. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бондарев</surname><given-names>В. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Bondarev</surname><given-names>V. P.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Филиал федерального государственного учреждения «48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации» - «Вирусологический центр», Сергиев Посад</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Virological Centre, Branch of Central Research Institute No. 48 of the Ministry of Defense of the Russian Federation, Sergiev Posad</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>13</day><month>05</month><year>2020</year></pub-date><volume>54</volume><issue>11-12</issue><fpage>17</fpage><lpage>20</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; ООО «Издательство ОКИ», 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">ООО «Издательство ОКИ»</copyright-holder><copyright-holder xml:lang="en">ООО «Издательство ОКИ»</copyright-holder><license xlink:href="https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/273">https://www.antibiotics-chemotherapy.ru/jour/article/view/273</self-uri><abstract><p>Изучение эффективности рибавирина в отношении вируса Западного Нила в постоянных культурах клеток свидетельствует о том, что исследуемый препарат в высоких концентрациях эффективно подавляет репродукцию вируса (коэффициент ингибирования 100%). Рибавирин при инъекционном применении в течение 7 суток в дозе 20 мг/кг по схеме экстренной профилактики высокоэффективно защищает от гибели 85 % белых мышей, инфицированных вирусом Западного Нила в дозе 10 ЛД50.</p></abstract><trans-abstract xml:lang="en"><p>Investigation of the efficacy of ribavirin against the West Nile virus in standard cell cultures showed that in high concentrations it inhibited the virus reproduction (the inhibition coefficient of 100%). In the experiments on albino mice infected with the West Nile virus in a dose of 10 LD50 ribavirin was used in the form of injections in a dose of 20 mg/kg for 7 days in the scheme of urgent prophylaxis and proved to be highly efficient in protection of the animals from death (85-percent survival).</p></trans-abstract><kwd-group xml:lang="ru"><kwd>лихорадка Западного Нили</kwd><kwd>рибавирин</kwd><kwd>противовирусная эффективность</kwd><kwd>культура клеток</kwd></kwd-group><kwd-group xml:lang="en"><kwd>West Nile fever</kwd><kwd>ribavirin</kwd><kwd>antiviral efficacy</kwd><kwd>cell culture</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Борисевич С.В., Бондарев В.П. Лихорадка Западного Нила: прошлое и настоящее. Мол. мед. 2008; 5: 47-51.</mixed-citation><mixed-citation xml:lang="en">Борисевич С.В., Бондарев В.П. Лихорадка Западного Нила: прошлое и настоящее. Мол. мед. 2008; 5: 47-51.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Odelola H.A. Antiviral activity of Virazole on replication of viruses isolated in Nigeria. Current Chemotherapy / Siegenthaler W., Lathy R. eds. Washington: American Society of Microbiology. 1978; 1: 3343-3345.</mixed-citation><mixed-citation xml:lang="en">Odelola H.A. Antiviral activity of Virazole on replication of viruses isolated in Nigeria. Current Chemotherapy / Siegenthaler W., Lathy R. eds. Washington: American Society of Microbiology. 1978; 1: 3343-3345.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Jordan I., Briese T., Fisher N. et al. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis 2000; 182: 1214-1217.</mixed-citation><mixed-citation xml:lang="en">Jordan I., Briese T., Fisher N. et al. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis 2000; 182: 1214-1217.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson J.F., Rahal J.J. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Inf Dis 2002; 8: 1: 107-108.</mixed-citation><mixed-citation xml:lang="en">Anderson J.F., Rahal J.J. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Inf Dis 2002; 8: 1: 107-108.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ben-Nathan D., Lustig S., Tam G. et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 2003; 188: 5-12.</mixed-citation><mixed-citation xml:lang="en">Ben-Nathan D., Lustig S., Tam G. et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 2003; 188: 5-12.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Shimoni Z., Niven V.J., Pitlick S., Bulvic S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Inf Dis 2001; 7: 4: 759.</mixed-citation><mixed-citation xml:lang="en">Shimoni Z., Niven V.J., Pitlick S., Bulvic S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Inf Dis 2001; 7: 4: 759.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ben-Nathan D., Gershoni-Yahalom O., Samina I. et al. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis 2009; 17: 9: 18.</mixed-citation><mixed-citation xml:lang="en">Ben-Nathan D., Gershoni-Yahalom O., Samina I. et al. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis 2009; 17: 9: 18.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Planitzer Ch.B., Modrof J., Kreil Th.R. West Nile virus neutralization by US plasma-derived immunoglobulin products. J Infect Dis 2007; 196: 435-440.</mixed-citation><mixed-citation xml:lang="en">Planitzer Ch.B., Modrof J., Kreil Th.R. West Nile virus neutralization by US plasma-derived immunoglobulin products. J Infect Dis 2007; 196: 435-440.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Oliphant T., Engle M., Nybakken G. et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005; 11: 522-530.</mixed-citation><mixed-citation xml:lang="en">Oliphant T., Engle M., Nybakken G. et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005; 11: 522-530.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gould L.H., Sui J., Foellmer H. et al. Protective and therapeutic capacity of human single chain Fv-Fc fusion proteins against West Nile virus. J Virol 2005; 79: 14606-14613.</mixed-citation><mixed-citation xml:lang="en">Gould L.H., Sui J., Foellmer H. et al. Protective and therapeutic capacity of human single chain Fv-Fc fusion proteins against West Nile virus. J Virol 2005; 79: 14606-14613.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nybakken G., Oliphant T., Johnson S. et al. Structural basis for neutralization of a therapeutic antibody against West Nile virus. Nature 2005; 437: 764-769.</mixed-citation><mixed-citation xml:lang="en">Nybakken G., Oliphant T., Johnson S. et al. Structural basis for neutralization of a therapeutic antibody against West Nile virus. Nature 2005; 437: 764-769.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hall R.A., Khromykh A.A. ChimeriVax-West Nile vaccine. Curr Opin Mol Ther 2007; 9: 5: 498-504.</mixed-citation><mixed-citation xml:lang="en">Hall R.A., Khromykh A.A. ChimeriVax-West Nile vaccine. Curr Opin Mol Ther 2007; 9: 5: 498-504.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Логинова С.Я., Ковальчук А.В., Борисевич С.В. и др. Противовирусная эффективность индуктора интерферона амиксина в отношении экспериментальной формы лихорадки Западного Нила. Вопр. вирусол. 2004; 2: 14-17.</mixed-citation><mixed-citation xml:lang="en">Логинова С.Я., Ковальчук А.В., Борисевич С.В. и др. Противовирусная эффективность индуктора интерферона амиксина в отношении экспериментальной формы лихорадки Западного Нила. Вопр. вирусол. 2004; 2: 14-17.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Петров В.А. Лечение больных лихорадкой Западного Нила // Мат. расширенного пленума проблемной комиссии «Арбовирусы» и науч.-практ. конф. «Арбовирусы и арбовирусные инфекции», 17-20 октября 2006 г. Астрахань. М.: 2007; 204-208.</mixed-citation><mixed-citation xml:lang="en">Петров В.А. Лечение больных лихорадкой Западного Нила // Мат. расширенного пленума проблемной комиссии «Арбовирусы» и науч.-практ. конф. «Арбовирусы и арбовирусные инфекции», 17-20 октября 2006 г. Астрахань. М.: 2007; 204-208.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М.: 2005.</mixed-citation><mixed-citation xml:lang="en">Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М.: 2005.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
